The future of clinical pharmacology in the UK

Lancet

Volumn 367, Issue 9516, 2006, Pages 1051-

  Breckenridge, Alasdair ^a   Dollery, Colin ^b   Rawlins, Michael ^c   Walport, Mark ^d  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DRUG EFFICACY; DRUG INDUSTRY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; LETTER; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL PROFESSION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; UNITED KINGDOM; HUMAN; NOTE;

DRUG INDUSTRY; GREAT BRITAIN; HUMANS; PHARMACOLOGY, CLINICAL;

EID: 33645729183     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68460-2     Document Type: Letter

References (2)

1. Maxwell S., and Webb D. Clinical pharmacology-too young to die?. Lancet 367 (2006) 799-800
2. Royal Society. Personalised medicines: hopes and realities (2005), The Royal Society, London